Sequential Chemotherapy / Targeted Agents
Posted: Wed Dec 09, 2009 8:16 am
FYI, there are more papers documenting the benefits for sequential chemotherapy or sequential targeted agents. This may make particular sense for ASPS because it is a relatively slower growing cancer. Molecular profiling results suggest that there are different populations of cells too that can grow up and become resistant.
I'll add a link to a presentation that showed sequential targeted antiangiogenesis inhibitors like sutent, pazopanib, etc. seem to be more effective in kidney cancer than a single agent alone, but I came across this application for a patent - suggesting that if an IGFR1 inhibitor is given after cytotoxic chemotherapy, it is more effective than either alone. In applying for their patent, they included tests on Ewing sarcoma cells.
It was an interesting application to come across because we've been enjoying a good stability on R1507 after an unsuccessful run at metronomic chemotherapy - but one of the agents for the metronomic we used was Cytoxan, one of the combinations used in the patent application.
I'll add a link to a presentation that showed sequential targeted antiangiogenesis inhibitors like sutent, pazopanib, etc. seem to be more effective in kidney cancer than a single agent alone, but I came across this application for a patent - suggesting that if an IGFR1 inhibitor is given after cytotoxic chemotherapy, it is more effective than either alone. In applying for their patent, they included tests on Ewing sarcoma cells.
It was an interesting application to come across because we've been enjoying a good stability on R1507 after an unsuccessful run at metronomic chemotherapy - but one of the agents for the metronomic we used was Cytoxan, one of the combinations used in the patent application.